79 results
Page 2 of 4
6-K
EX-99.1
gnx6o8t9h kelet6
29 Jun 22
InflaRx Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19
8:30am
6-K
EX-99.1
dgapkzrsy2vebt
12 May 22
Current report (foreign)
8:30am
6-K
EX-99.3
n3hcmjw3
12 May 22
Current report (foreign)
8:30am
6-K
EX-99.1
8pg8o8
7 Apr 22
Current report (foreign)
4:01pm
6-K
EX-99.1
ewwlie w4vw2p
31 Mar 22
InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients
4:51pm
6-K
EX-99.1
43gkshcu
24 Mar 22
InflaRx Reports Full Year 2021 Financial and Operating Results
8:40am
6-K
EX-99.1
6y38mh2 n1ft3gcjh
17 Mar 22
InflaRx Receives Corrected Advice Letter from FDA Related to Phase III Program for Vilobelimab in Hidradenitis Suppurativa
7:30am
6-K
EX-99.1
y3fiv 0w2d
8 Mar 22
InflaRx Announces Vilobelimab Trial in Pyoderma Gangrenosum Selected for Late-Breaker Oral Presentation at 2022 AAD Annual Meeting
7:51am
6-K
EX-99.1
t3f406vqw tco4v6cd0
28 Feb 22
InflaRx Provides Update on Development Plans for Vilobelimab in Hidradenitis Suppurativa
7:30am
6-K
EX-99.1
wvl781 lhb
16 Feb 22
InflaRx Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell Carcinoma
7:30am
6-K
EX-99.1
r0ga9
10 Jan 22
InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor
7:30am
6-K
EX-99.1
r7bcd 051tdkf9
5 Jan 22
Current report (foreign)
7:30am
6-K
EX-99.1
34sdxgyal2z oi
15 Nov 21
Current report (foreign)
7:36am
6-K
EX-99.1
0ij wzrxx2zet
5 Nov 21
Current report (foreign)
7:30am
6-K
EX-99.3
s3bu4xr jch4
5 Nov 21
Current report (foreign)
7:30am
6-K
EX-99.2
fxyqll
5 Nov 21
Current report (foreign)
7:30am
6-K
EX-99.1
vd3 lgajv
27 Oct 21
InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum
7:31am
6-K
EX-99.1
zm8zavknmqn 7po
19 Oct 21
Current report (foreign)
7:30am
6-K
EX-99.1
ygq3l
12 Oct 21
InflaRx Completes Enrollment of Vilobelimab Phase III Study in Severe COVID-19
7:30am